NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)PRNewsWire • 04/15/24
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar DepressionPRNewsWire • 04/08/24
NRx Pharmaceuticals (NRXP) Upgraded to Strong Buy: Here's What You Should KnowZacks Investment Research • 04/04/24
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdatePRNewsWire • 04/01/24
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End HighlightsPRNewsWire • 03/28/24
UPDATE: NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024PRNewsWire • 03/26/24
NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UKPRNewsWire • 03/25/24
NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 28, 2024PRNewsWire • 03/21/24
NRx Pharmaceuticals Announces Results of the Vote Held During the Special Meeting of ShareholdersPRNewsWire • 03/21/24
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Plan to Distribute Shares of HOPE Therapeutics and Royalty Rights on Ketamine Sales to Existing NRx ShareholdersPRNewsWire • 03/18/24
NRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine)PRNewsWire • 03/11/24
NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar DepressionPRNewsWire • 03/04/24
NRx Pharmaceuticals Announces Definitive Purchase Agreement for Common, Unregistered Shares at $0.38 per SharePRNewsWire • 03/01/24
NRx Pharmaceuticals, Inc. Announces Pricing of $1.5 Million Underwritten Public Offering of Common Stock Together with investor Commitment for Additional $1 millionPRNewsWire • 02/27/24
NRx Pharmaceuticals (Nasdaq:NRXP) Launches HOPE Therapeutics, Inc. at the BIO CEO & Investor Conference 2024PRNewsWire • 02/26/24
NRx Pharmaceuticals (Nasdaq:NRXP) to Launch HOPE Therapeutics, Inc. at the BIO CEO & Investor Conference 2024PRNewsWire • 02/20/24
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Advance of $5 Million Milestone Payment from Partners Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. (1975.TW)PRNewsWire • 02/12/24
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Reports Comments by Strategic Partner Lotus Pharmaceutical Co. Ltd. (1975.TW) in Recent Financial ReportPRNewsWire • 02/09/24
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces the Incorporation of HOPE Therapeutics, Inc., and Planned Share Dividend/Royalty CouponPRNewsWire • 02/05/24
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Completion of Enrollment of its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar DepressionPRNewsWire • 01/22/24